Which has better valuation & earnings, INNV or BLLN?

Billiontoone has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $853.70M 1.84 -$30.31M -$0.09 N/A Billiontoone $305.11M 19.00 $7.45M $0.55 229.24

Does the media refer more to INNV or BLLN?

In the previous week, InnovAge had 1 more articles in the media than Billiontoone. MarketBeat recorded 4 mentions for InnovAge and 3 mentions for Billiontoone. InnovAge's average media sentiment score of 0.86 beat Billiontoone's score of 0.63 indicating that InnovAge is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SHC or INNV?

Sotera Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.25 $77.94M $0.41 42.32 InnovAge $853.70M 1.84 -$30.31M -$0.09 N/A

Does the media prefer SHC or INNV?

In the previous week, Sotera Health had 4 more articles in the media than InnovAge. MarketBeat recorded 8 mentions for Sotera Health and 4 mentions for InnovAge. Sotera Health's average media sentiment score of 1.25 beat InnovAge's score of 0.86 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InnovAge 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INNV or RDNT?

RadNet has higher revenue and earnings than InnovAge. RadNet is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $853.70M 1.84 -$30.31M -$0.09 N/A RadNet $2.04B 2.37 -$18.65M -$0.18 N/A

Is INNV or RDNT more profitable?

RadNet has a net margin of -0.66% compared to InnovAge's net margin of -1.22%. RadNet's return on equity of 2.77% beat InnovAge's return on equity. Company Net Margins Return on Equity Return on Assets InnovAge -1.22% -4.73% -2.20% RadNet -0.66% 2.77% 0.97%

Does the media prefer INNV or RDNT?

In the previous week, RadNet had 5 more articles in the media than InnovAge. MarketBeat recorded 9 mentions for RadNet and 4 mentions for InnovAge. RadNet's average media sentiment score of 1.35 beat InnovAge's score of 0.86 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RadNet 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INNV or VCYT?

Veracyte has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $853.70M 1.84 -$30.31M -$0.09 N/A Veracyte $517.15M 8.73 $66.35M $1.09 51.94

Is INNV or VCYT more profitable?

Veracyte has a net margin of 16.25% compared to InnovAge's net margin of -1.22%. Veracyte's return on equity of 9.07% beat InnovAge's return on equity. Company Net Margins Return on Equity Return on Assets InnovAge -1.22% -4.73% -2.20% Veracyte 16.25% 9.07% 8.38%

Does the media refer more to INNV or VCYT?

In the previous week, Veracyte had 1 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for Veracyte and 4 mentions for InnovAge. Veracyte's average media sentiment score of 0.90 beat InnovAge's score of 0.86 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CAI or INNV?

In the previous week, InnovAge had 2 more articles in the media than Caris Life Sciences. MarketBeat recorded 4 mentions for InnovAge and 2 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.88 beat InnovAge's score of 0.86 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InnovAge 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

InnovAge (INNV) Competitors

$11.56 +0.37 (+3.31%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$11.56 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

INNV vs. BLLN, SHC, RDNT, VCYT, and CAI

Should you buy InnovAge stock or one of its competitors? MarketBeat compares InnovAge with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InnovAge include Billiontoone (BLLN), Sotera Health (SHC), RadNet (RDNT), Veracyte (VCYT), and Caris Life Sciences (CAI). These companies are all part of the "healthcare" industry.

How does InnovAge compare to Billiontoone?

InnovAge (NASDAQ:INNV) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Billiontoone has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.84	-$30.31M	-$0.09	N/A
Billiontoone	$305.11M	19.00	$7.45M	$0.55	229.24

In the previous week, InnovAge had 1 more articles in the media than Billiontoone. MarketBeat recorded 4 mentions for InnovAge and 3 mentions for Billiontoone. InnovAge's average media sentiment score of 0.86 beat Billiontoone's score of 0.63 indicating that InnovAge is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Billiontoone has a net margin of 0.00% compared to InnovAge's net margin of -1.22%. Billiontoone's return on equity of 0.00% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Billiontoone	N/A	N/A	N/A

InnovAge currently has a consensus target price of $7.00, suggesting a potential downside of 39.45%. Billiontoone has a consensus target price of $126.00, suggesting a potential downside of 0.06%. Given Billiontoone's stronger consensus rating and higher possible upside, analysts plainly believe Billiontoone is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

12.3% of InnovAge shares are owned by institutional investors. 1.0% of InnovAge shares are owned by insiders. Comparatively, 50.2% of Billiontoone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Billiontoone beats InnovAge on 11 of the 15 factors compared between the two stocks.

How does InnovAge compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Sotera Health had 4 more articles in the media than InnovAge. MarketBeat recorded 8 mentions for Sotera Health and 4 mentions for InnovAge. Sotera Health's average media sentiment score of 1.25 beat InnovAge's score of 0.86 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InnovAge	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health has a net margin of 9.91% compared to InnovAge's net margin of -1.22%. Sotera Health's return on equity of 39.73% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
InnovAge	-1.22%	-4.73%	-2.20%

Sotera Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.25	$77.94M	$0.41	42.32
InnovAge	$853.70M	1.84	-$30.31M	-$0.09	N/A

Sotera Health currently has a consensus target price of $20.25, suggesting a potential upside of 16.71%. InnovAge has a consensus target price of $7.00, suggesting a potential downside of 39.45%. Given Sotera Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Sotera Health is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 1.0% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sotera Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Summary

Sotera Health beats InnovAge on 16 of the 16 factors compared between the two stocks.

How does InnovAge compare to RadNet?

InnovAge (NASDAQ:INNV) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

InnovAge has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, RadNet has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

RadNet has a net margin of -0.66% compared to InnovAge's net margin of -1.22%. RadNet's return on equity of 2.77% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
RadNet	-0.66%	2.77%	0.97%

InnovAge currently has a consensus target price of $7.00, indicating a potential downside of 39.45%. RadNet has a consensus target price of $87.43, indicating a potential upside of 42.00%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80

12.3% of InnovAge shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 1.0% of InnovAge shares are owned by company insiders. Comparatively, 5.6% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, RadNet had 5 more articles in the media than InnovAge. MarketBeat recorded 9 mentions for RadNet and 4 mentions for InnovAge. RadNet's average media sentiment score of 1.35 beat InnovAge's score of 0.86 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has higher revenue and earnings than InnovAge. RadNet is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.84	-$30.31M	-$0.09	N/A
RadNet	$2.04B	2.37	-$18.65M	-$0.18	N/A

Summary

RadNet beats InnovAge on 15 of the 17 factors compared between the two stocks.

How does InnovAge compare to Veracyte?

InnovAge (NASDAQ:INNV) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

InnovAge has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Veracyte has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.84	-$30.31M	-$0.09	N/A
Veracyte	$517.15M	8.73	$66.35M	$1.09	51.94

12.3% of InnovAge shares are held by institutional investors. 1.0% of InnovAge shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Veracyte has a net margin of 16.25% compared to InnovAge's net margin of -1.22%. Veracyte's return on equity of 9.07% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Veracyte	16.25%	9.07%	8.38%

InnovAge currently has a consensus target price of $7.00, indicating a potential downside of 39.45%. Veracyte has a consensus target price of $55.88, indicating a potential downside of 1.30%. Given Veracyte's stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Veracyte	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Veracyte had 1 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for Veracyte and 4 mentions for InnovAge. Veracyte's average media sentiment score of 0.90 beat InnovAge's score of 0.86 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats InnovAge on 15 of the 17 factors compared between the two stocks.

How does InnovAge compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and InnovAge (NASDAQ:INNV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

InnovAge has higher revenue and earnings than Caris Life Sciences. InnovAge is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.40	-$68.09M	-$7.61	N/A
InnovAge	$853.70M	1.84	-$30.31M	-$0.09	N/A

In the previous week, InnovAge had 2 more articles in the media than Caris Life Sciences. MarketBeat recorded 4 mentions for InnovAge and 2 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.88 beat InnovAge's score of 0.86 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InnovAge	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.3% of InnovAge shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Caris Life Sciences has a net margin of 3.75% compared to InnovAge's net margin of -1.22%. Caris Life Sciences' return on equity of 98.28% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
InnovAge	-1.22%	-4.73%	-2.20%

Caris Life Sciences presently has a consensus target price of $26.11, suggesting a potential upside of 68.24%. InnovAge has a consensus target price of $7.00, suggesting a potential downside of 39.45%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Caris Life Sciences is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Caris Life Sciences beats InnovAge on 10 of the 15 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INNV vs. The Competition

Export

Metric	InnovAge	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57B	$9.50B	$7.06B	$12.20B
Dividend Yield	N/A	1.62%	2.67%	9.41%
P/E Ratio	-128.44	25.73	27.14	23.63
Price / Sales	1.84	19.19	582.30	111.98
Price / Cash	N/A	141.08	49.81	58.78
Price / Book	6.57	6.11	10.28	6.01
Net Income	-$30.31M	$179.69M	$3.60B	$331.99M
7 Day Performance	0.52%	-3.06%	-1.27%	-0.63%
1 Month Performance	7.14%	-1.50%	-1.67%	-3.04%
1 Year Performance	201.04%	9.52%	18.25%	13.30%

InnovAge Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INNV InnovAge	1.7883 of 5 stars	$11.56 +3.3%	$7.00 -39.4%	+201.0%	$1.57B	$853.70M	N/A	2,440	Positive News
BLLN Billiontoone	2.1291 of 5 stars	$132.53 +5.9%	$126.00 -4.9%	N/A	$5.76B	$305.11M	N/A	620
SHC Sotera Health	3.8277 of 5 stars	$17.40 -0.1%	$20.25 +16.4%	+41.1%	$4.97B	$1.16B	22.05	3,000	News Coverage Positive News
RDNT RadNet	3.6065 of 5 stars	$61.87 +2.0%	$87.43 +41.3%	+7.2%	$4.77B	$2.04B	N/A	11,264	News Coverage
VCYT Veracyte	1.9355 of 5 stars	$59.53 +4.0%	$55.88 -6.1%	+124.2%	$4.57B	$517.15M	54.61	790	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INNV) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InnovAge (INNV) Competitors

INNV vs. BLLN, SHC, RDNT, VCYT, and CAI

How does InnovAge compare to Billiontoone?

Summary

How does InnovAge compare to Sotera Health?

Summary

How does InnovAge compare to RadNet?

Summary

How does InnovAge compare to Veracyte?

Summary

How does InnovAge compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InnovAge (INNV) Competitors

INNV vs. BLLN, SHC, RDNT, VCYT, and CAI

How does InnovAge compare to Billiontoone?

Which has better valuation & earnings, INNV or BLLN?

Does the media refer more to INNV or BLLN?

Is INNV or BLLN more profitable?

Do analysts rate INNV or BLLN?

Do insiders & institutionals hold more shares of INNV or BLLN?

Summary

How does InnovAge compare to Sotera Health?

Does the media prefer SHC or INNV?

Is SHC or INNV more profitable?

Which has stronger valuation and earnings, SHC or INNV?

Do analysts rate SHC or INNV?

Do institutionals and insiders hold more shares of SHC or INNV?

Which has more volatility & risk, SHC or INNV?

Summary

How does InnovAge compare to RadNet?

Which has more volatility & risk, INNV or RDNT?

Is INNV or RDNT more profitable?

Do analysts rate INNV or RDNT?

Do institutionals and insiders have more ownership in INNV or RDNT?

Does the media prefer INNV or RDNT?

Which has preferable earnings & valuation, INNV or RDNT?

Summary

How does InnovAge compare to Veracyte?

Which has more volatility & risk, INNV or VCYT?

Which has stronger valuation & earnings, INNV or VCYT?

Do institutionals and insiders believe in INNV or VCYT?

Is INNV or VCYT more profitable?

Do analysts rate INNV or VCYT?

Does the media refer more to INNV or VCYT?

Summary

How does InnovAge compare to Caris Life Sciences?

Which has stronger earnings & valuation, CAI or INNV?

Does the media refer more to CAI or INNV?

Do institutionals & insiders have more ownership in CAI or INNV?

Is CAI or INNV more profitable?

Do analysts rate CAI or INNV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools